Topoisomerase II Inhibitors
"Topoisomerase II Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Descriptor ID |
D059005
|
MeSH Number(s) |
D27.505.519.389.892.750 D27.505.954.248.794.750
|
Concept/Terms |
Topoisomerase II Inhibitors- Topoisomerase II Inhibitors
- Inhibitors, Topoisomerase II
- DNA Type 2 Topoisomerase Inhibitors
- Topoisomerase 2 Inhibitors
- Inhibitors, Topoisomerase 2
- DNA Topoisomerase II Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase II Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase II Inhibitors".
This graph shows the total number of publications written about "Topoisomerase II Inhibitors" by people in this website by year, and whether "Topoisomerase II Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2018 | 4 | 0 | 4 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase II Inhibitors" by people in Profiles.
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
-
The toxin from a ParDE toxin-antitoxin system found in Pseudomonas aeruginosa offers protection to cells challenged with anti-gyrase antibiotics. Mol Microbiol. 2019 02; 111(2):441-454.
-
Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2018 12; 113:43-54.
-
Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. J Cell Biochem. 2019 03; 120(3):3149-3159.
-
In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. Tuberculosis (Edinb). 2018 09; 112:83-88.
-
Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 2014 Feb 15; 74(4):1200-13.
-
The dynamics of DNA topoisomerase IIalpha in living cells. Methods Mol Biol. 2009; 582:233-44.
-
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res. 1994 Feb 15; 54(4):1042-8.